Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer (PAM07)

This study has been terminated.
(recruitment prematurely stopped due to a lack of eligible patients.)
Information provided by (Responsible Party):
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Identifier:
First received: April 18, 2008
Last updated: March 12, 2013
Last verified: March 2013

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer.

PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.

Condition Intervention Phase
Chemotherapeutic Agent Toxicity
Pancreatic Cancer
Drug: daltéparine
Drug: Chemotherapy at the investigator's discretion
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas

Resource links provided by NLM:

Further study details as provided by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR):

Primary Outcome Measures:
  • Thromboembolic events [ Time Frame: during study treatment ]
    number of thromboembolic events during anticoagulation treatment

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: at 6 months ]
  • Overall survival [ Time Frame: at one year ]
  • Tolerance of regimens [ Time Frame: each cycle ]

Enrollment: 42
Study Start Date: October 2007
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: chemotherapy
chemotherapy at investigator's discretion
Drug: Chemotherapy at the investigator's discretion
Experimental: dalteparin
dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
Drug: daltéparine Drug: Chemotherapy at the investigator's discretion

Detailed Description:



  • To demonstrate that preventive anticoagulation with dalteparin reduces the number of thromboembolic events.
  • To determine the number of thromboembolic events occurring with preventive anticoagulation.


  • To determine survival without thrombotic event.
  • To determine progression-free and overall survival.
  • To determine time to response of tumor.
  • To assess tolerance of these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to participating center and WHO performance status (0-1 vs 2). Patients are randomized to 1 of 4 treatment arms.

  • Arm A: Patients receive chemotherapy at investigator's discretion
  • Arm B Patients receive chemotherapy at investigator's discretion and dalteparin In all arms, treatment repeats in the absence of disease progression or unacceptable toxicity.

Blood and plasma samples are obtained at baseline and periodically during study. Blood is examined for biomarkers, resistance to activated protein C, and mutations (Leiden V factor, mutation G20210A, and the factor II gene). Thrombin generation and factors VIIa and VIII are assessed in plasma.

After completion of study therapy, patients are followed periodically.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the pancreas

    • Metastatic disease
    • Not amenable to treatment
    • No localized or locally advanced disease
  • Measurable disease (metastatic or primary tumor) defined as ≥ 2 cm by CT scan or ≥ 1 cm by spiral CT scan or MRI
  • No progressive thrombo-embolic disease
  • No adenocarcinoma of the biliary tract or ampulla of Vater
  • No known CNS metastases


  • WHO performance status 0-2
  • Life expectancy > 12 weeks
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL
  • Alkaline phosphatase < 5 times normal
  • Bilirubin < 1.5 times normal
  • Creatinine < 1.5 times normal
  • Creatinine clearance < 30 mL/min
  • Pain controlled or stabilized via analgesic therapy
  • Affiliation with social security system
  • Not pregnant or nursing
  • No controlled or uncontrolled jaundice
  • No contraindication to study drugs
  • No cardiovascular accident (myocardial infarction, cerebral vascular accident) within the past 6 months
  • No serious cardiac and/or respiratory disease
  • No other cancer in the past 5 years except the following cancers, provided they have been completely resected:

    • Skin cancer
    • Localized melanoma
    • Carcinoma in situ of the cervix
  • No history of thrombophilia
  • No history of heparin-induced thrombocytopenia
  • No uncontrolled or persistent hypercalcemia
  • No psychological, familial, social, and/or geographical condition that precludes participation in the study


  • No prior hematologic therapy for metastatic disease
  • No prior abdominal radiotherapy
  • No concurrent corticosteroids as anti-emetic therapy
  • No other concurrent anticoagulation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00662688

Centre Hospitalier de Meaux
Meaux, France, 77104
Centre Hospitalier Intercommunal Le Raincy - Montfermeil
Montfermeil, France, 93370
Hopital Bichat - Claude Bernard
Paris, France, 75018
Hopital Saint Antoine
Paris, France, 75571
CHU Pitie-Salpetriere
Paris, France, 75651
Hopital Foch
Suresnes, France, 92151
Sponsors and Collaborators
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Principal Investigator: Benoist Chibauldel, MD Hopital Saint Antoine
  More Information

Responsible Party: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Identifier: NCT00662688     History of Changes
Other Study ID Numbers: CDR0000593019
EUDRACT 2007-002115-59
Study First Received: April 18, 2008
Last Updated: March 12, 2013

Keywords provided by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR):
chemotherapeutic agent toxicity
adenocarcinoma of the pancreas
stage IV pancreatic cancer
recurrent pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017